Protocol Ledger

Clinical Cooperative Network · Consolidated Sponsor Hub

ECOG-ACRIN Cancer Research Group: Clinical Trials & FDA Approval Profile

ECOG-ACRIN Cancer Research Group (Global / Institutional) sponsors 32 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 28 active protocols (9 recruiting now), 0 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)12.5%
Median Closed Enrollment vs National (145 pts)138 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for ECOG-ACRIN Cancer Research Group
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)32
Active Pipeline (Recruiting Now)28 (9)
Completed vs Stopped Early0 / 4 (12.5%)
Median Closed Actual Enrollment138 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With ECOG-ACRIN Cancer Research Group
Hospital Research SiteLocationShared Protocols
Northwestern Memorial and Lurie Cancer CenterChicago, IL22
Marshfield Medical Center-MarshfieldMarshfield, WI22
Mercy Hospital SouthSaint Louis, MO21

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by ECOG-ACRIN Cancer Research Group
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05863195Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With UnresectPhase IIIRECRUITING
NCT07001748Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer SpreadPhase II/IIIRECRUITING
NCT07068074Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-StagePhase IIIRECRUITING
NCT06319027Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE TrialPhase IIRECRUITING
NCT03937635Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering MyelomaPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the ECOG-ACRIN Cancer Research Group Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI